J Brian Szender1, Kevin H Eng2, Junko Matsuzaki3, Anthony Miliotto3, Sacha Gnjatic4, Takemasa Tsuji3, Kunle Odunsi5. 1. Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, United States; Department of Epidemiology and Environmental Health, State University of New York at Buffalo, Buffalo, NY 14214, United States. 2. Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. 3. Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. 4. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States. 5. Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, United States; Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. Electronic address: kunle.odunsi@roswellpark.org.
Abstract
OBJECTIVES: To characterize the association between major histocompatibility complex (MHC) types and spontaneous antibody development to the cancer testis (CT) antigen NY-ESO-1. METHODS: Tumor expression of NY-ESO-1 and serum antibodies to NY-ESO-1 were characterized in addition to human leukocyte antigen (HLA) type for patients with epithelial ovarian cancer. HLA types were assigned to structure-based superfamilies and statistical associations were examined. HLA types were compared to existing reference libraries of HLA frequencies in a European-Caucasian American population. RESULTS: Out of 126 patients identified, 81% were expression positive and 48% had spontaneous antibody responses to NY-ESO-1. There was an association between HLA-B superfamily and seropositivity among patients with tumors expressing NY-ESO-1 (p<0.001). The differences in HLA-B superfamily assignment were driven by HLA-B44. Among all patients, the B27 superfamily was over-represented compared with the general population (p<0.001). CONCLUSIONS: HLA type appears to be associated with spontaneous anti-CT antigen antibodies, as well as with the overall risk of ovarian cancer.
OBJECTIVES: To characterize the association between major histocompatibility complex (MHC) types and spontaneous antibody development to the cancer testis (CT) antigen NY-ESO-1. METHODS:Tumor expression of NY-ESO-1 and serum antibodies to NY-ESO-1 were characterized in addition to human leukocyte antigen (HLA) type for patients with epithelial ovarian cancer. HLA types were assigned to structure-based superfamilies and statistical associations were examined. HLA types were compared to existing reference libraries of HLA frequencies in a European-Caucasian American population. RESULTS: Out of 126 patients identified, 81% were expression positive and 48% had spontaneous antibody responses to NY-ESO-1. There was an association between HLA-B superfamily and seropositivity among patients with tumors expressing NY-ESO-1 (p<0.001). The differences in HLA-B superfamily assignment were driven by HLA-B44. Among all patients, the B27 superfamily was over-represented compared with the general population (p<0.001). CONCLUSIONS:HLA type appears to be associated with spontaneous anti-CT antigen antibodies, as well as with the overall risk of ovarian cancer.
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: E Stockert; E Jäger; Y T Chen; M J Scanlan; I Gout; J Karbach; M Arand; A Knuth; L J Old Journal: J Exp Med Date: 1998-04-20 Impact factor: 14.307
Authors: Joana R Lérias; Georgia Paraschoudi; Eric de Sousa; João Martins; Carolina Condeço; Nuno Figueiredo; Carlos Carvalho; Ernest Dodoo; Mireia Castillo-Martin; Antonio Beltrán; Dário Ligeiro; Martin Rao; Alimuddin Zumla; Markus Maeurer Journal: Front Cell Dev Biol Date: 2020-01-23